Discontinuation of thioridazine. Risks must be balanced
- PMID: 12399356
- PMCID: PMC1124456
- DOI: 10.1136/bmj.325.7370.967/a
Discontinuation of thioridazine. Risks must be balanced
Comment on
-
Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs.BMJ. 2002 Jun 22;324(7352):1519-21. doi: 10.1136/bmj.324.7352.1519. BMJ. 2002. PMID: 12077046 Free PMC article. Review. No abstract available.
References
-
- Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215–2220. - PubMed
-
- Vander Ben Borre R. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double blind placebo-controlled cross-over study. Acta Psychiatrica Scandinavica. 1993;87:167–171. - PubMed
-
- Mos J, Van Aken HH, Van Oorschot R, Olivier B. Chronic treatment with eltoprazine does not lead to tolerance in its anti-aggressive actions, in contrast to haloperidol. Eur Neuropsychopharmacol. 1996;6:1–7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources